{ "biomarker_id": "AN6320-1", "biomarker_canonical_id": "AN6320", "condition": { "recommended_name": { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "COVID-19", "description": "A Coronavirus infectious disease that is characterized by fever, cough and shortness of breath and that has_material_basis_in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a subtype of Betacoronavirus pandemicum." }, "synonyms": [ { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "2019 Novel Coronavirus (2019-nCoV)", "description": "" }, { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "2019-nCoV infection", "description": "" }, { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "COVID19", "description": "" }, { "id": "DOID:0080600", "resource": "Disease Ontology", "url": "https://disease-ontology.org/term/DOID:0080600", "name": "SARS-CoV-2 infection", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "COVID-19", "description": "A disease caused by infection with severe acute respiratory syndrome coronavirus 2." }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019 novel coronavirus infection", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019-nCoV infection", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "coronavirus disease 2019", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "severe acute respiratory syndrome coronavirus 2 infectious disease", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019 novel coronavirus", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "2019-nCoV", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "SARS-CoV-2", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "SARS-coronavirus 2", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "beta-CoV", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "beta-CoVs", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "betacoronavirus", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "severe acute respiratory syndrome coronavirus 2", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "-CoV", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "-CoVs", "description": "" }, { "id": "MONDO:0100096", "resource": "MONDO", "url": "https://monarchinitiative.org/disease/MONDO:0100096", "name": "-coronavirus", "description": "" } ], "id": "DOID:0080600" }, "biomarker_component": [ { "biomarker": "increased CEACAM5 level", "assessed_biomarker_entity_id": "P06731-1", "assessed_entity_type": "protein", "assessed_biomarker_entity": { "recommended_name": "Carcinoembryonic antigen-related cell adhesion molecule 5", "synonyms": [ { "synonym": "Carcinoembryonic antigen" }, { "synonym": "CEA" }, { "synonym": "Meconium antigen 100" }, { "synonym": "Carcinoembryonic antigen-related cell adhesion molecule 5" }, { "synonym": "CEA cell adhesion molecule 5" } ] }, "specimen": [ { "name": "blood", "namespace": "UBERON", "id": "0000178", "url": "http://purl.obolibrary.org/obo/UBERON_0000178", "loinc_code": "" } ], "evidence_source": [ { "id": "AN6320-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1" }, { "id": "32540459", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32540459", "tags": [ "assessed_biomarker_entity", " assessed_biomarker_entity_id", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "In conclusion, the serum CEA levels were found to be increased in patients with severe or critically severe SARS-CoV-2 infection." } ] }, { "id": "32347972", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32347972", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries.;|Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly.;|This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ] }, { "id": "32333071", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32333071", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "On laboratory work-up, mildly elevated carcinoembryonic antigen (CEA = 9.8 ng/mL, normal range up to 5 ng/mL) was detected." } ] }, { "id": "32504736", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32504736", "tags": [ "assessed_biomarker_entity", " biomarker", " specimen" ], "evidence_list": [ { "evidence": "Additional cancer biomarkers such as carcinoembryonic antigen (CEA), carbohydrate antigens 125 and 153, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) increased significantly in many critical cases. [DOI:10.2139/ssrn.3552854] In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease.;|In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease.;|In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients.;|Tumor biomarkers, such as carcino embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated." } ] } ] } ], "best_biomarker_role": [ { "role": "monitoring" } ], "evidence_source": [ { "id": "AN6320-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1" }, { "id": "32540459", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32540459", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "In conclusion, the serum CEA levels were found to be increased in patients with severe or critically severe SARS-CoV-2 infection." } ] }, { "id": "32347972", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32347972", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Increases in levels of Human epididymis protein 4 (HE4), Cytokeratin-19 fragment (CYFRA21-1) Carcinoembryonic antigen (CEA), Carbohydrate antigen 125 (CA125), Carbohydrate antigen 153 (CA153), Squamous cell carcinoma antigen (SCC), Carbohydrate antigen 199 (CA199). There were positive associations between levels of C-reactive protein and levels of HE4 (R= 0.631, p<0.001), CYFRA21-1 (R= 0.431, p<0.001), CEA (R= 0.316, p<0.001), SCC (R= 0.351, p<0.001), CA153 (R= 0.359, p<0.001) and CA125 (R= 0.223, p=0.031). We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute lung injuries.;|Significant increases in levels of human epididymis protein 4 (HE4), cytokeratin-19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 , and 153 Squamous cell carcinoma antigen (SCC) and CA199 increased significantly.;|This is the first report with such a substantial evaluation of cancer biomarkers on a large patient population of COVID-19. Our data demonstrate that levels of serum HE4, CYFRA21-1, CEA, CA125, CA153, SCC, and NSE are positively associated with CRP, a crucial factor in correlation with the severity of the disease. We concluded that elevations of serum cancer biomarkers positively correlated with the pathological progressions of COVID-19, demonstrating diffuse and acute pathophysiological injuries in COVID-19." } ] }, { "id": "32333071", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32333071", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "On laboratory work-up, mildly elevated carcinoembryonic antigen (CEA = 9.8 ng/mL, normal range up to 5 ng/mL) was detected." } ] }, { "id": "32504736", "database": "PubMed", "url": "https://glygen.org/publication/PubMed/32504736", "tags": [ "best_biomarker_role", " condition" ], "evidence_list": [ { "evidence": "Additional cancer biomarkers such as carcinoembryonic antigen (CEA), carbohydrate antigens 125 and 153, squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE) increased significantly in many critical cases. [DOI:10.2139/ssrn.3552854] In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease.;|In addition, the significant differences of plasma level of CEA, CYFRA21- 1 and SCCA were observed among the subgroups of severity of disease and clinical outcome (Table 1) and plasma level of CEA, CYFRA21-1, SCCA were significantly increased with the advance serverity of disease.;|In short, we concluded that the concentrations of tumor biomarkers of CEA, CYFRA21-1, NSE, SCCA, ProGRP were elevated in COVID-19 patients, and that CEA, CYFRA21-1, SCCA could predict the clinical outcome of COVID-19 patients.;|Tumor biomarkers, such as carcino embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), squamous cell carcinoma antigen (SCCA) and Pro-Gastrin Releasing Peptide (ProGRP), were elevated." } ] } ], "crossref": [ { "id": "AN6320-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1", "categories": [ "Biomarkers" ] } ], "citation": [ { "title": "Prognostic value of carcinoembryonic antigen on outcome in patients with coronavirus disease 2019.", "journal": "The Journal of infection", "authors": "Yu J, Yang Z, Zhou X, Wu D, Chen J, Zhang L, Tong L, Nie L", "date": "2020", "reference": [ { "type": "PubMed", "id": "32540459", "url": "https://glygen.org/publication/PubMed/32540459" } ], "evidence": [ { "id": "BD0279-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1" } ] }, { "title": "Elevations of serum cancer biomarkers correlate with severity of COVID-19.", "journal": "Journal of medical virology", "authors": "Wei X, Su J, Yang K, Wei J, Wan H, Cao X, Tan W, Wang H", "date": "2020", "reference": [ { "type": "PubMed", "id": "32347972", "url": "https://glygen.org/publication/PubMed/32347972" } ], "evidence": [ { "id": "AN6320-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1" } ] }, { "title": "A case of COVID-19 lung infection first detected by [18F]FDG PET-CT.", "journal": "European journal of nuclear medicine and molecular imaging", "authors": "Amini H, Divband G, Montahaei Z, Dehghani T, Kaviani H, Adinehpour Z, Akbarian Aghdam R, Rezaee A, Vali R", "date": "2020", "reference": [ { "type": "PubMed", "id": "32333071", "url": "https://glygen.org/publication/PubMed/32333071" } ], "evidence": [ { "id": "AN6320-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1" } ] }, { "title": "Tumor biomarkers predict clinical outcome of COVID-19 patients.", "journal": "The Journal of infection", "authors": "He B, Zhong A, Wu Q, Liu X, Lin J, Chen C, He Y, Guo Y, Zhang M, Zhu P, Wu J, Wang C, Wang S, Xia X", "date": "2020", "reference": [ { "type": "PubMed", "id": "32504736", "url": "https://glygen.org/publication/PubMed/32504736" } ], "evidence": [ { "id": "AN6320-1", "database": "BiomarkerKB", "url": "https://biomarkerkb.org/biomarker/AN6320-1" } ] } ], "section_stats": [ { "table_id": "biomarker_component", "table_stats": [ { "field": "total", "count": 1 } ], "sort_fields": [ "biomarker", "assessed_biomarker_entity_id", "assessed_entity_type", "assessed_biomarker_entity.recommended_name" ] }, { "table_id": "citation", "table_stats": [ { "field": "total", "count": 4 } ], "sort_fields": [ "title", "journal", "authors", "date" ] } ] }